SERNOVA CORP. news, videos and press releases - Page 2
For more news please use our advanced search feature.
SERNOVA CORP. - More news...
SERNOVA CORP. - More news...
- Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications
- Successful Results Using Sernova’s Cell Pouch System™ with Evotec’s iPSC-Derived Islet-like Clusters for Type 1 Diabetes Presented at the 4th IPITA / HSCI / JDRF Summit
- Two Independent Proxy Advisory Firms, Including Glass Lewis & Co. LLC., Recommend Sernova’s Shareholders Vote FOR all Management Nominees on Management’s White Proxy
- UPDATE -- Institutional Shareholder Services Inc. Recommends Sernova’s Shareholders Vote FOR all Management Nominees on Management’s White Proxy
- Institutional Shareholder Services Inc. Recommends Senova’s Shareholders Vote FOR all Management Nominees on Management’s White Proxy
- EQS-News: Sernova to Present at 2023 Alliance for Regenerative Medicine Cell & Gene Meeting on the Med
- Sernova to Present at 2023 Alliance for Regenerative Medicine Cell & Gene Meeting on the Med
- Sernova Responds to Dissident Shareholders’ Misleading Statements and Provides Corporate Updates
- EQS-News: Sernova: Abstract on First Cohort of its Phase 1/2 Study Involving Islet Transplantation into Cell Pouch Selected for Oral Podium Presentation at American Diabetes Association 83rd Scientific Sessions
- Sernova Announces Abstract on First Cohort of its Phase 1/2 Study Involving Islet Allotransplantation into Pre-vascularized Cell Pouch™ Selected for Oral Podium Presentation at American Diabetes Association 83rd Scientific Sessions 2023
- EQS-News: Sernova Announces Upcoming Podium Presentation of iPSC and Cell Pouch™ Combination Treatment for Type One Diabetes at the 4th IPITA / HSCI / JDRF Summit
- Sernova Announces Upcoming Podium Presentation of iPSC and Cell Pouch™ Combination Treatment for Type One Diabetes at the 4th IPITA / HSCI / JDRF Summit
- EQS-News: Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes
- Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes
- EQS-News: Sernova to Participate in Upcoming Roth and Oppenheimer Investor Conferences
- Sernova to Participate in Upcoming Roth and Oppenheimer Investor Conferences
- EQS-News: Sernova Announces Advancements with its Novel Cell Pouch System(TM) to Preserve Thyroid Function Following Total Thyroidectomy
- Sernova Announces Advancements with its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy
- EQS-News: Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes
- Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes
- EQS-News: Sernova Announces CEO Succession Plan and Expanded Management Team
- Sernova Corp. Announces CEO Succession Plan and Expanded Management Team
- Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of its US Phase 1/2 Clinical Trial for Type 1 Diabetes
- Sernova to Participate in the Stifel Healthcare Conference
- Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes
- Sernova to Participate in the Roth Inaugural Healthcare Opportunities Conference
- Sernova Announces Full Exercise of Share Purchase Warrants Expiring September 22, 2022
- Sernova to Present at H.C. Wainwright Annual Global Investment Conference and LifeSci Partners HealthTech Symposium
- Sernova Announces the Appointment of Daniel Mahony, Ph.D. to its Board of Directors
- Sernova Receives Second Tranche Equity Investment from Evotec of $6.8 Million at a Price of $2.50 Per Share
